Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.
Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.
复制标题
DOI：
10.1155/2015/731361
复制
发表时间：
2015
影响因子：
--
通讯作者：
Cha S
中科院分区：
文献类型：
--
作者：
Barajas RF Jr;Pampaloni MH;Clarke JL;Seo Y;Savic D;Hawkins RA;Behr SC;Chang SM;Berger M;Dillon WP;Cha S
我们介绍了使用单一模式氟米索硝唑 (FMISO) PET/MR 成像来无创评估贝伐珠单抗治疗复发性高级别胶质瘤患者的生物效应的初步经验。在该指数患者中，贝伐单抗治疗导致非增强肿瘤的发展，其特征是扩散减少，并且在维持 CBF 和 CBV 的情况下 FMISO 摄取显着减少。这些观察结果表明，可以利用 FMISO PET/MR 成像捕获治疗后的复发性高级神经胶质瘤中发生的组织缺氧和血管正常化之间的动态生物相互作用。
We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging.